(EMAILWIRE.COM, January 05, 2017 ) Publisher's, "11 Beta-Hydroxysteroid Dehydrogenase Type 1 (11ßHSD1) Inhibitors-Pipeline Insights, 2016", report provides in depth insights on the pipeline drugs and their development activities around the 11 Beta-Hydroxysteroid Dehydrogenase Type 1 (11ßHSD1) Inhibitors. The Publisher's Report covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. Publisher's Report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for 11 Beta-Hydroxysteroid Dehydrogenase Type 1 (11ßHSD1) Inhibitors. Publisher's Report also assesses the 11 Beta-Hydroxysteroid Dehydrogenase Type 1 (11ßHSD1) Inhibitors therapeutics by Monotherapy, Combination products, Molecule type and Route of Administration.

For more information about this report: http://www.reportsweb.com/11-beta-hydroxysteroid-dehydrogenase-inhibitors-pipeline-insights-2016

Report Scope

- The report provides competitive pipeline landscape of 11 Beta-Hydroxysteroid Dehydrogenase Type 1 (11ßHSD1) Inhibitors
- The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
- Coverage of the 11 Beta-Hydroxysteroid Dehydrogenase Type 1 (11ßHSD1) Inhibitors pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
- The report reviews key players involved in the therapeutics development for 11 Beta-Hydroxysteroid Dehydrogenase Type 1 (11ßHSD1) Inhibitors and also provide company profiling
- The report also gives the information of dormant and discontinued pipeline projects
- Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
- Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type

Reason to Buy

- Complete MOA intelligence and complete understanding over therapeutics development for 11 Beta-Hydroxysteroid Dehydrogenase Type 1 (11ßHSD1) Inhibitors
- Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine.
- Devise corrective measures for pipeline projects by understanding 11 Beta-Hydroxysteroid Dehydrogenase Type 1 (11ßHSD1) Inhibitors pipeline depth and focus of Indication therapeutics
- Developing strategic initiatives to support your drug development activities.
- Optimize your portfolio and keep you in touch with the rapidly changing pharmaceutical markets, and make the best decisions for your business.
- Develop and design in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
- Gaining a Full Picture of the Competitive Landscape for Evidencebased Decisions

Request Sample Copy at http://www.reportsweb.com/inquiry&RW0001338764/sample

Table of Contents

- 11 Beta-Hydroxysteroid Dehydrogenase Type 1 (11ßHSD1) Inhibitors Overview
- 11 Beta-Hydroxysteroid Dehydrogenase Type 1 (11ßHSD1) Inhibitors Disease Associated
- 11 Beta-Hydroxysteroid Dehydrogenase Type 1 (11ßHSD1) Inhibitors Pipeline Therapeutics
- 11 Beta-Hydroxysteroid Dehydrogenase Type 1 (11ßHSD1) Inhibitors Therapeutics under Development by Companies
- 11 Beta-Hydroxysteroid Dehydrogenase Type 1 (11ßHSD1) Inhibitors Filed and Phase III Products
- Comparative Analysis
- 11 Beta-Hydroxysteroid Dehydrogenase Type 1 (11ßHSD1) Inhibitors Phase II Products
- Comparative Analysis
- 11 Beta-Hydroxysteroid Dehydrogenase Type 1 (11ßHSD1) Inhibitors Phase I and IND Filed Products
- Comparative Analysis
- 11 Beta-Hydroxysteroid Dehydrogenase Type 1 (11ßHSD1) Inhibitors Discovery and Pre-Clinical Stage Products
- Comparative Analysis
- Drug Candidate Profiles
- 11 Beta-Hydroxysteroid Dehydrogenase Type 1 (11ßHSD1) Inhibitors - Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Combination Products
- Assessment by Route of Administration
- Assessment by Molecule Type
- 11 Beta-Hydroxysteroid Dehydrogenase Type 1 (11ßHSD1) Inhibitors - Discontinued Products
- 11 Beta-Hydroxysteroid Dehydrogenase Type 1 (11ßHSD1) Inhibitors - Dormant Products
- Companies Involved in Therapeutics Development for 11 Beta-Hydroxysteroid Dehydrogenase Type 1 (11ßHSD1) Inhibitors

Inquire before Buying at http://www.reportsweb.com/inquiry&RW0001338764/buying

Contact Information:
ReportsWeb.com
Priya Sisodia
Tel: +1-646-491-9876
Email us


----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results